Skip to main
BMY

Bristol-Myers (BMY) Stock Forecast & Price Target

Bristol-Myers (BMY) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 21%
Hold 50%
Sell 7%
Strong Sell 0%

Bulls say

Bristol-Myers Squibb is poised to see continued success in the future due to its strong focus on immuno-oncology and upcoming clinical data readouts for key treatments such as ADEPT-2 and ADMILPARANT. However, potential risks in clinical trials and competition from other innovations could pose challenges for the company's earnings in the future. It is important to closely monitor the progress of these clinical trials and the competitive landscape in the market.

Bears say

Bristol-Myers Squibb is heavily reliant on the US market, with close to 70% of its total sales coming from the country. While the company is a leader in immuno-oncology and has a strong pipeline, there are downside risks such as potential competition in rare cardiovascular diseases, clinical failure of pipeline programs, and regulatory delays. These risks could negatively impact the company's growth and performance.

Bristol-Myers (BMY) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 21% recommend Buy, 50% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bristol-Myers (BMY) Forecast

Analysts have given Bristol-Myers (BMY) a Buy based on their latest research and market trends.

According to 14 analysts, Bristol-Myers (BMY) has a Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $61.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $61.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bristol-Myers (BMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.